Cargando…

CIK Cells and HDAC Inhibitors in Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4–5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephan, David, Weiher, Hans, Schmidt-Wolf, Ingo G.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454858/ https://www.ncbi.nlm.nih.gov/pubmed/28468247 http://dx.doi.org/10.3390/ijms18050945

Ejemplares similares

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)

Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells
por: Rombo, Roman, et al.
Publicado: (2016)

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
por: Sharma, Amit, et al.
Publicado: (2021)

Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer
por: Dehno, Mojgan Naghizadeh, et al.
Publicado: (2020)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
por: Esser, Laura, et al.
Publicado: (2016)

A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells
por: Garofano, Francesca, et al.
Publicado: (2022)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
por: Li, Yutao, et al.
Publicado: (2022)

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
por: Imai, Yoichi, et al.
Publicado: (2019)

High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells
por: Garofano, Francesca, et al.
Publicado: (2020)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
por: Hirano, Mitsuhito, et al.
Publicado: (2021)

Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials
por: Zhang, Ying, et al.
Publicado: (2021)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
por: Schwamborn, Katharina, et al.
Publicado: (2011)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

CD300LG improves the cytotoxic activity of CIK
por: Wang, Qiuyue, et al.
Publicado: (2017)

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells
por: Bremm, Melanie, et al.
Publicado: (2019)

NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation
por: Wu, Xiaolong, et al.
Publicado: (2021)

Comparative Proteomic Analysis of Lysine Acetylation in Fish CIK Cells Infected with Aquareovirus
por: Guo, Hong, et al.
Publicado: (2017)

The destiny of the resistance/susceptibility against GCRV is controlled by epigenetic mechanisms in CIK cells
por: Shang, Xueying, et al.
Publicado: (2017)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2015)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
por: Sun, Xiaoyang, et al.
Publicado: (2019)

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
por: Besse, L, et al.
Publicado: (2017)

CIK细胞及其在肺癌治疗中的研究进展
Publicado: (2011)

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2023)

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
por: Ma, Yue, et al.
Publicado: (2012)

Natural Killer T Cells Subsets in Cancer, Functional Defects in Prostate Cancer and Implications for Immunotherapy
por: Nowak, Michael, et al.
Publicado: (2011)

HDAC inhibitors stimulate viral transcription by multiple mechanisms
por: Balakrishnan, Lata, et al.
Publicado: (2008)

Effect of CIK on multidrug-resistance reversal and increasing the sensitivity of ADR in K562/ADR cells
por: WANG, LEI, et al.
Publicado: (2014)

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
por: Liu, Guiyuan, et al.
Publicado: (2022)

CD4(+) T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
por: Liu, Shaochuan, et al.
Publicado: (2022)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Cik1 and Vik1 accessory proteins confer distinct functions to the kinesin-14 Kar3
por: Bergman, Zane J., et al.
Publicado: (2023)

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
por: Huang, Fang-I, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6rf6012pan68u5r1u19tcbj2k9